GlassScriptPhysician profile
Crystal Bales
NPI 1417481516
$2,888.05
in general payments reported to CMS, 2019-2025
26 companies · $777 in 2025
The $777 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $317 · 2023: $491 · 2024: $885 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,153.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $370.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $364.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $297.07 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $277.94 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $260.27 | 2023-2025 | |
| Amgen INC. | $215.58 | 2023-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.42 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $162.32 | 2021-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $124.93 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $100.55 | 2022-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $86.41 | 2024-2025 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $77.87 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $66.01 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $40.07 | 2023-2024 | Gemtesa |
| Urovant Sciences INC | $39.48 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.41 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $24.19 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.70 | 2022 | |
| Abbott Laboratories | $17.33 | 2024 | Freestyle Libre 3 |
| Medtronic, INC. | $17.23 | 2025 | Interstim |
| Genentech USA, INC. | $16.47 | 2021 | |
| Ethicon US, LLC | $15.88 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.52 | 2021 | |
| Esperion Therapeutics, INC. | $15.21 | 2024 | Nexletol |
| Exact Sciences Corporation | $14.92 | 2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $12.88 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Bales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.